Alkem Labs receives EIR for St. Louis facility; stock dips 1%

The pharma company said its facility at St. Louis in the USA has received an establishment inspection report (EIR) from the US drug regulator.

May 12, 2020 02:05 IST India Infoline News Service

alkem
Alkem Laboratories in an exchange filing announced that its facility at St. Louis in the USA has received an establishment inspection report (EIR) from the US drug regulator.

“In furtherance to the intimation captioned "USFDA Inspection at Alkem’s manufacturing facility located at St. Louis, USA" on February 7, 2020, this is to inform you that USFDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility and the inspection has now been closed by the USFDA,” the pharma company said.

The stock is currently trading at Rs2,576.45, down by Rs19.25 or 0.74% from its previous closing of Rs2,595.70 on the BSE.

The scrip opened at Rs2,597.10 and has touched a high and low of Rs2,597.10 and Rs2,526.85 respectively.

Related Story